Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins and early pregnancy loss
In press.
Meldrum DR, Scott RT, Levy MJ, Alper MM, Noyes N. Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins and early pregnancy loss. Fertil Steril. 2008. In press.
Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. a randomized controlled trial
EM Kolibianakis EG Papanikolaou M Camus H Tournaye AC Van Steirteghem P Devroey 2006 Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial Hum Reprod. 21 352 357
Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pretreatment
J Bellver C Albert E Lambarta A Pellicer 2007 Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pretreatment Fertil Steril. 87 1098 1101
The ganirelix dose-finding study group: A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (puregon)
Anonymous 1998 The ganirelix dose-finding study group: A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (puregon) Hum Reprod. 13 3023 3031
Selective use of leuprolide acetate in women undergoing superovulation with intrauterine insemination results in significant improvement in pregnancy outcome
DL Manzi S Dumez LB Scott JC Nulsen 1995 Selective use of leuprolide acetate in women undergoing superovulation with intrauterine insemination results in significant improvement in pregnancy outcome Fertil Steril. 63 866 873
Timing ovulation for intrauterine insemination with a GnRH antagonist
JL Gomez-Palomares B Julia B Acevedo-Martin M Martinez-Burgos ER Hernandez E Ricciarelli 2005 Timing ovulation for intrauterine insemination with a GnRH antagonist Hum Reprod. 20 368 372
Treatment with GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: Results of a double-blind, placebo-controlled, multicenter trial
CB Lambalk A Leader F Olivennes 2006 Treatment with GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicenter trial Hum Reprod. 21 632 639
Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: A meta-analysis
2
IP Kosmas A Tatsioni EM Kolibianakis 2007 Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis Fertil Steril. 90 2 367 372
Timing of FSH administration for ovarian stimulation in normo-ovulatory women: Comparison of an early or a mid follicular phase initiation of a short-term treatment
I Cedrin-Durnerin N Massin J Galey-Fontaine 2006 Timing of FSH administration for ovarian stimulation in normo-ovulatory women: comparison of an early or a mid follicular phase initiation of a short-term treatment Hum Reprod. 21 2941 2647